+91 99104 22296 | info@pharmabridge.co.in
Home Products About Us Quality & Compliance Insights Contact Us
Home Oncology APIs Portfolio Ponatinib T315I BCR::ABL Kinase Inhibitor
CAS # 943319-70-8 Targeted TKI Grade (MW 532.56 g/mol)

Ponatinib T315I BCR::ABL Kinase Inhibitor

Ponatinib is a targeted tyrosine kinase inhibitor (C29H27F4N6O) inhibiting ABL/BCR::ABL, including the T315I mutant form in Philadelphia chromosome-positive ALL and Chronic Myeloid Leukemia (CML).

Assay / Purity ≥ 98.5% (C29H27F4N6O)
Physical Appearance Off-White to Yellow Powder
Documentation CoA / DMF / GMP
Email Technical Specs

Direct Procurement Quote

Fill details to receive commercial terms and Certificate of Analysis (CoA).

Technical Specifications Summary

Chemical / Product Name Ponatinib T315I BCR::ABL Kinase Inhibitor
CAS Registry Number 943319-70-8
Standard Grade Targeted TKI Grade (MW 532.56 g/mol)
Assay / Purity ≥ 98.5% (C29H27F4N6O)
Appearance Off-White to Yellow Powder

Formulation & Industry Applications

Ph+ ALL Oral Tablets
CML T315I Mutation Regimens